Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 29, 2008

View Archived Issues

Cerebral ischemia greatly increases protein sumoylation

Cypress acquires Proprius for USD 37.5 million in cash

ProMetic Life Sciences enters license agreement with Kedrion for two hyperimmunes

Soluble CD40 ligand a marker of Alzheimer's disease severity, progression

YM-202074 confers neuroprotection in a stroke model

Alimera enters agreement with Emory to develop new drugs for ophthalmic diseases

Genzyme reported Q4 2007 highlights

AstraZeneca presents update on clinical development of Recentin in NSCLC and colorectal cancer

Recent Pharmacopeia patent reports novel treatment option for autoimmune diseases

Novel agents for treating HCV infection disclosed in recent Genelabs and Gilead patents

New treatments for diabetes and related disorders described in recent patent literature

CNV reduction with picropodophyllin in experimental models

Targeting CCR3 may provide benefit in CNV associated with AMD

ISS recommends that Pharmion stockholders vote for merger agreement with Celgene

Intercell reports results from phase I clinical trial of IC-31 adjuvanted flu vaccine

7TM Pharma reports positive results from two phase I clinical studies of TM-30339 in obesity

MorphoSys and Sigma-Aldrich enter agreement for recombinant research antibodies

GSK and Theravance initiate phase IIb trial of beta-agonist GW-642444 for COPD

FDA accepts and grants priority review to Sirion's NDA for Durezol for ocular inflammation

Positive pharmacokinetic study results of once-daily ondansetron

Anadys initiates phase I ANA-773 trial in cancer patients

Athersys reports results for phase I safety study of novel obesity drug

Evotec commences phase II smoking cessation trial with EVT-302

FDA approves Arcalyst for cryopyrin-associated periodic syndromes (CAPS)

Preliminary results reported from phase III NGX-4010 trial in HIV-DSP

Japan approves Herceptin for early treatment of HER2-positive breast cancer

FDA approves Luvox CR Extended-Release capsules for SAD and OCD therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...